Exploring the role of drug-metabolising enzymes in antidepressant side effects.

ABSTRACT:

Rationale

Cytochrome P450 enzymes are important in the metabolism of antidepressants. The highly polymorphic nature of these enzymes has been linked to variability in antidepressant metabolism rates, leading to hope regarding the use of P450 genotyping to guide treatment. However, evidence that P450 genotypic differences underlie the variation in treatment outcomes is inconclusive.

Objectives

We explored the links between both P450 genotype and serum concentrations of antidepressant with antidepressant side effects, using data from the Genome-Based Therapeutic Drugs for Depression Project (GENDEP), which is a large (n = 868), pharmacogenetic study of depressed individuals treated with escitalopram or nortriptyline.

Methods

Patients were genotyped for the enzymes CYP2C

SUBMITTER: Hodgson K 

PROVIDER: S-EPMC4480333 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature